A group of US senators has urged federal regulators to address the issue of illegal online sales of abortion pills, emphasizing the connection to overseas supply chains, including those in India. In a letter to FDA Commissioner Martin Makary, the lawmakers emphasized the need for immediate action to prevent the distribution of unauthorized versions of mifepristone and misoprostol in the US market. They highlighted the detrimental impact of these illegal sales on women’s health and the FDA’s consumer protection mission.
The senators expressed concerns about the risks posed by unregulated online access to these drugs, stating that it could lead to serious health implications for women and increase the likelihood of coerced abortions. They pointed out that a significant portion of these drugs sold through foreign websites originate from various manufacturers in India. The lawmakers highlighted the rapid growth of the online market, citing instances where tens of thousands of packages were shipped to multiple US states within a year.
Identifying four primary channels for the distribution of these drugs, including US-based telehealth clinics, foreign clinics, informal networks, and online pharmacies, the senators underscored the lack of proper oversight and prescriptions in many cases. They raised concerns about websites falsely claiming to offer FDA-approved drugs while actually selling unapproved versions sourced from overseas manufacturers. Additionally, safety issues were highlighted, with some platforms advising users against disclosing their medication use to healthcare providers.
The senators called on the FDA to enhance enforcement measures, including issuing warning letters, taking action against website domains, and improving coordination with customs and postal authorities to intercept illicit shipments. They also requested criminal investigations, citing a previous case involving the unauthorized sale of abortion pills sourced from India. Led by Senator Bill Cassidy, the letter was co-signed by Senators Steve Daines, James Lankford, Cindy Hyde-Smith, and Lindsey Graham, who urged the FDA to provide details of enforcement actions by April 8.
